Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 8,886

Document Document Title
WO/2007/140551A2
The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.  
WO/2007/143066A2
Provided is a method for determining whether an individual is likely to be susceptible to radiation pneumonitis from radiation therapy and for developing a treatment based on the determination of susceptibility. The method involves measu...  
WO/2007/140551A3
The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.  
WO/2007/139153A1
It is intended to provide a function-improving agent for cerebral dysfunction caused by an environmental chemical. According to the invention, the function-improving agent for cerebral dysfunction caused by an environmental chemical cont...  
WO/2007/135241A3
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  
WO/2007/135241A2
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  
WO/2007/135242A1
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  
WO/2007/133076A2
The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol and/or proline containing compositions that are particularly useful for the t...  
WO/2007/133076A3
The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol and/or proline containing compositions that are particularly useful for the t...  
WO/2007/132418A1
The present invention concerns to the use of salicylate in the treatment of mammal intoxications caused by the herbicide paraquat (PQ). It was achieved, for the first time, 100% of survival 30 days after the administration to Wistar rats...  
WO/2007/125946A1
Disclosed are: an antioxidant agent which comprises, as an active ingredient, a peptide having an antioxidative effect and an adiponectin production-promoting effect and comprising the amino acid sequence represented by the formula: His-...  
WO/2007/124610A1
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said an...  
WO/2007/125832A1
A new action of Helipyrone A is now found. As a useful application of Helipyrone A, the following agent is disclosed: a singlet oxygen scavenger, an anti-skin-aging agent, an anti-wrinkle agent, an anti-sagging agent, an agent for improv...  
WO/2007/124734A2
A compound of the formula A-R-X or pharmaceutically acceptable salts thereof can be used to manufacture a pharmaceutical preparation which serves to prevent or treat cancers, pathological sequelae of alcohol abuse, viral hepatitis, steat...  
WO/2007/124734A3
A compound of the formula A-R-X or pharmaceutically acceptable salts thereof can be used to manufacture a pharmaceutical preparation which serves to prevent or treat cancers, pathological sequelae of alcohol abuse, viral hepatitis, steat...  
WO/2007/123284A1
The present invention relates to an alpha lipoic acid capsule composition stabilized in aqueous phase, which can effectively prevent alpha lipoic acid from decomposing due to external environmental conditions, such as water, temperature,...  
WO/2007/119367A1
Tetrahydrobiopterin (BH4) to be used as a pharmaceutical has an excellent efficacy, therefore, expansion of use or application thereof is considered. However, because BH4 is expensive and unstable to oxidation, its application to other t...  
WO/2007/118276A1
The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or ot...  
WO/2007/118967A1
This invention relates to the use of cholest-4-in-3-one derivatives to obtain a cytoprotective medicine, excluding a neuroprotective medicine.  
WO/2007/116916A1
[PROBLEMS] To provide a liquid drug preparation for oral preparation by which the labor at drug-taking can be saved to thereby reduce patient burden and which enables safe drug-taking. [MEANS FOR SOLVING PROBLEMS] A liquid drug preparati...  
WO/2007/114791A1
The invention relates to a pharmaceutical composition containing 250 to 5000 millimoles per liter of lactate or lactic acid, 0.5 to 1.99 millimoles per liter of calcium and optionally 2 to 10 millimoles per liter of potassium. The invent...  
WO/2007/114461A1
Disclosed is a process for production of a composition having a carotenoid content of 80% or more, which comprises: extracting a culture of a microorganism, a condensation product of the culture or a dried product of the culture or the c...  
WO/2007/109893A1
The present invention relates to compositions and methods for reducing the cellular toxicity of a fume, particularly in relation to pulmonary inflammation, cytokine imbalance and lung disease. Plant extracts to be used with the compositi...  
WO/2007/109892A1
The present invention relates to compositions and methods for reducing the concentration of noxious substances in gases and smoke. Filters comprising plant extracts, such as parenchyma tissue extract and mesophyll cell extract, are also ...  
WO/2007/108438A1
A component capable of promoting glutathione production with enhanced effectiveness, and an external composition for use in promoting of glutathione production. Both γ-tocopherol and δ-tocopherol exhibit strikingly high glutathione pro...  
WO/2007/109804A2
The present invention relates to extracts of cinnamon species plant material prepared by supercritical CO2 extractions methods.  
WO/2007/105547A1
The invention provides methods for improving the absorbability and antioxidant ability of myricetin in the body. Either of the methods can be achieved by binding one or a plurality of glucosyl groups to the oxygen atom at the 3 or 3' pos...  
WO/2007/101365A1
The invention discloses a new flavane compound of formula (I) and its uses. The new flavane compound has antiinflammatory, antiallergic, antiviral and antioxidative effect, which is used to prepare antiinflammatory medicines or antialler...  
WO/2007/101349A1
A composition comprising Evodia rutaecarpia, green tea, black pepper and Cissus quandrangulans extracts, yohimbine and caffeine anhydrous for the purpose of reducing body fat mass and thus promoting weight loss The ingredients of the com...  
WO/2007/102735A1
The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there i...  
WO/2007/102572A1
A novel inhibitor for cellular aging which can effectively and fundamentally inhibit cellular aging. This inhibitor for cellular aging contains, as the active ingredient, a substance capable of inhibiting the expression of a gene encodin...  
WO/2007/101068A3
A method of treating and/or managing cystic fibrosis in a patient by administering an electrolyzed saline solution containing hypohalous acid. Preferably, the hypohalous acid is hypochlorous acid. Also provided is a method of treating an...  
WO/2007/099828A1
Nitrogenous heterocyclic derivatives represented by the general formula (I) which each bind specifically to NR1/NR2B receptor and are useful as NR2B receptor antagonists (particularly analgesic for cancer pain or neuroprotectant); pharma...  
WO/2007/095760A1
The invention includes novel compounds, including but not limited to formula A and formula B, and an improved delivery method. These compounds and methods are useful in preventing or treating diseases or conditions associated with or cau...  
WO/2007/096078A1
The invention relates to the use of resveratrol, a derivative, metabolite or analogue thereof for promoting the wellness state of a mammal or for changing gene expression profiles in older adult mammals towards conformity with expression...  
WO/2007/094498A1
[PROBLEMS] To provide a food composition effectively exerting an antioxidant effect in vivo, in particular, a food composition which is useful as a health food (including a food with health claims (a food for specified health uses and a ...  
WO/2007/092458A1
The present application discloses the use of compounds exhibiting both acetylcholinesterase (AchE) inhibition properties and σ-1 receptor agonist capacities for treating a mammal exposed to an exogenous neurotoxic agent, in particular n...  
WO/2007/086565A1
Disclosed is a growth hormone secretion regulator or anti-aging agent comprising aspartic acid and valine as active ingredients. Also disclosed is a pharmaceutical, food, nutritional supplement or feeding stuff comprising the growth horm...  
WO/2007/085679A1
The invention relates to the preparation of beta-carboline-type molecules from amino acids from natural products and foods, which act as reversible inhibitors of the enzyme monoaminooxidase (MAO). The reversible MAO inhibitors are used f...  
WO/2007/080560A2
The present invention concerns to the process of induction ofde novo synthesis of P-glycoprotein (P-gp) to be used as a treatment of xenobiotic-induced intoxications in mammals and, in particular, of paraquat (PQ)-induced intoxications (...  
WO/2007/080560A3
The present invention concerns to the process of induction ofde novo synthesis of P-glycoprotein (P-gp) to be used as a treatment of xenobiotic-induced intoxications in mammals and, in particular, of paraquat (PQ)-induced intoxications (...  
WO/2007/080787A1
The invention provides coenzyme Q10-containing compositions which are free from synthetic emulsifiers such as glycerol fatty acid esters, polyglycerol fatty acid esters, organic acid monoglycerides or sucrose fatty acid esters and which ...  
WO/2007/080201A1
The invention relates to the administration of low doses of IGF-I in ageing, owing to the neuroprotective, antioxidant and anabolic effects thereof and to the use of same in the preparation of products having a neuroprotective, antioxida...  
WO/2007/072869A1
Disclosed is an amorphous form of 3-(2-cyanophenyl)-5- (2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one.  
WO/2007/072868A1
Disclosed is a crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)- 1-phenyl-1,2-dihydropyridin-2-one which is characterized by having a diffraction peak at a diffraction angle (2θ±0.2˚) of 15.4˚ in the powder X-ray diffraction pattern.  
WO/2007/073006A1
Disclosed is an inducer for the increasing of the content of a cytoprotective amino acid (methionine and/or homocysteine) in a living body, which comprises at least one component selected from the group consisting of carbon monooxide, pr...  
WO/2007/066458A1
A method for producing yeast for extraction of a lipid-soluble component according to the invention comprises a growth step in which yeast having a lipid-soluble component to be extracted is grown in such a manner that the medium pH decr...  
WO/2007/066744A1
It is intended to provide a food, a drink and a food/drink material having improved EGCg absorbability, and a method of producing the same by improving the absorbability of EGCg to be taken. The contents of caffeine and/or epigallocatech...  
WO/2007/055105A1
Disclosed is a novel anthocyanin compound. Specifically disclosed is an anthocyanin compound represented by the following chemical formula [1].  
WO/2007/052794A1
A compound or salt thereof which has antioxidant activity and is effective in the treatment of ischemic organ diseases including arteriosclerosis, heart infarction, and brain infarction, in the treatment of diseases caused by oxidative c...  

Matches 601 - 650 out of 8,886